Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
IRVINE, Calif., Jan. 03, 2017 -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
| Event: | 35th Annual J.P. Morgan Healthcare Conference | |
| Date: | Wednesday, January 11, 2017 | |
| Time: | 8:00 am PT / 11:00 am ET | |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentations will be available for 90 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020
